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Abstract 
 
Postoperative residual curarisation (PORC) resulting from the use of non 
depolarising muscle relaxants continues to be a significant problem. It is associated 
with an increase in morbidity and may delay discharge from the recovery room, 
increasing financial costs. An objective measurement of neuromuscular functioning 
using an accelerometer is recommended to ensure patient safety. The aim of this 
study was to describe the occurrence of PORC in the recovery room in patients who 
have received intermediate acting NDMRs intraoperatively at CHBAH. 
 
This was a prospective, contextual and descriptive study. The study sample included 
ASA 1 to 3 adult patients who had received an intermediate acting NDMR during 
elective surgery and had given pre operative consent to participate in the study. 
Neuromuscular function was monitored using acceleromyography. A TOF ratio < 0.9 
was defined as having PORC. Data collection took place during December 2014 to 
February 2015. Data was analysed using descriptive and inferential statistics.  
 
The study sample consisted of 55 patients. Twenty five patients had a TOF ratio < 
0.9 on arrival in the recovery room. The occurrence of PORC was therefore 45.46%. 
Intraoperative neuromuscular monitoring was documented to have been done in 3 
(5.45%) of the patients. The most frequently used NDMRs were rocuronium 31 
(56.36%) and cisatracurium 9 (16.36%). There was no statistically significant 
differences in the occurrence of PORC relating to the NDMR used (p=0.72) but 
higher percentages were observed with cisatracurium 5 (55.56%). An 
anticholinesterase as reversal agent was used in 48 (87.27%) of the patients. PORC 
was significantly more frequent in patients who did not receive an anticholinesterase 
(85.71 vs. 39.58%, p=0.03). Three patients presented with a temperature < 35 °C. 
Incomplete neuromuscular recovery was more frequent in patients with a 
temperature < 35 °C, 2 (66.67%) compared to the patients with a temperature ≥ 35 
°C 23 (44.23%)  
 
PORC remains a clinical problem in the recovery room. To ensure patient safety 
objective neuromuscular monitoring needs to be performed. 
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Chapter 1: Overview of study 
 
In this chapter, a brief overview and summary regarding this research report 
will be presented. Topics covered include background, problem statement, 
aims and objectives, research assumptions, demarcation of the study field, 
ethical considerations, research methodology, significance of the study, 
validity and reliability and study outline.  
 
1.1 Background 
 
Non depolarizing muscle relaxants (NDMR) have been used in anaesthesia 
since the 1940s (1, 2). The use of an anticholinesterase as an antagonist 
became routine in the mid 1950s (1, 3). For more than 30 years numerous 
studies have identified that postoperative residual curarisation (PORC) occurs 
frequently in patients receiving long acting NDMRs (4-7). This has been 
shown to be true to a lesser extent for the intermediate acting agents despite 
the administration of anticholinesterase (4, 8). Intermediate acting NDMRs at 
2 × ED 95 (effective dose) typically have a duration of action lasting less than 
90 minutes while the longer acting agents have a duration of action greater 
than 90 minutes. An ED 95 dose is defined as the dose of neuromuscular 
blocking agent that reduces the twitch height by 95%. (9) 
 
Factors that have been shown to contribute towards PORC include using high 
doses of NDMRs, long acting NDMRs, administering the anticholinesterase 
early and hypothermia (10). Patients at a higher risk include those with 
neuromuscular and respiratory pathology; sleep apnoea as well as obese and 
elderly patients. NDMRs should therefore be used with caution in these 
patients (11). 
 
Research has identified that 83% of anaesthetists use their clinical judgement 
to determine if there is adequate motor function. The parameters most often 
used include: acceptable minute ventilation, five second hand grip, negative 
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inspiratory pressures greater than -30 cmH20, the ability to cough and a head 
lift for more than 5 to 10 seconds. (10, 12)  
 
Optimal conditions for the assessment of these parameters requires that 
patients be awake, co-operative and without any residual anaesthetic drugs 
which is normally impossible. Even in an awake patient during the 
postoperative phase, it is difficult to assess these parameters owing to factors 
such as pain. (6, 13) This implies that the anaesthetist’s assessment is likely 
to be inaccurate and that the incidence of residual paralysis may be higher 
than expected. Surveys have shown that anaesthetist estimate the incidence 
of PORC to be 1%(12). 
 
The recommended method of identifying PORC is with the use of a peripheral 
nerve stimulator. There are three types of peripheral nerve stimulators that 
can be used: mechanomyography (isometric contractions measured), 
electromyography (measures compound action potentials) and with an 
acceleromyography (measures the acceleration of muscular contractions). 
Modes of stimulation that can be used include tetanic, post tetanic, double 
burst and train of four (TOF) stimulation (14). PORC is predominantly 
identified by measuring the TOF ratio at the adductor pollicis using an 
acceleromyography and the measurement produced as a ratio of the highest 
and the lowest twitch height (15). A TOF ratio < 0.9 characterises the current 
definition of PORC and is associated with numerous complications such as 
hypoxia, weakness, impaired swallowing and respiratory failure which can 
result in brain death (8). Consequently, there are delays in discharge from the 
recovery room, prolonged intubation times and poor patient satisfaction.  
 
Currently there are no published guidelines internationally or locally 
advocating the routine use of a peripheral nerve stimulator e.g. 
acceleromyography in the objective assessment of neuromuscular function 
(12). Recommendations have been made advocating the routine utilisation of 
peripheral nerve stimulation in the intraoperative period to guide reversal. 
Anticholinesterase should only be administered once four twitches are present 
irrespective of fade, to prevent postoperative residual curarisation (16). Fade 
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is the progressive reduction of twitch height on the application of a TOF ratio 
stimulus (17). 
 
Anaesthetists in most European countries are of the opinion that after a single 
intubating dose of 2 × ED 95 of a NDMR of intermediate duration, 
anticholinesterase is not required after 90 minutes as there is spontaneous 
recovery (18). A case report by Cladius and Karacan (4) illustrated that the 
pharmacokinetic principles of the NDMR’s are not predictable and the routine 
administration of an anticholinesterase at the end of surgery may not be 
correctly timed. Repeated neuromuscular monitoring was carried out and 
anticholinesterase was administered after 215 minutes when two twitches 
appeared. Had neuromuscular monitoring not been carried out this patient 
would have presented to the recovery room with PORC. This case 
demonstrated that a number of factors contribute to a prolonged blockade and 
these factors are not always predictable, highlighting the necessity of 
neuromuscular monitoring. (4) 
 
Administration of an anticholinesterase is not always necessary. 
Neuromuscular recovery is complete if the TOF ratio ≥ 0.9. TOF ratio can also 
be used to calculate the dosage of neostigmine thereby limiting its side 
effects. At times neostigmine dosages as small as 0.015 mg/kg are adequate 
for complete reversal. (18) 
 
Studies indicate that the incidence of PORC is between 17 and 64% of 
patients presenting in the recovery room after receiving NDMR. Of these 3% 
will develop significant morbidity and mortality such as brain injury and death. 
A further 15% are estimated to develop hypoxia, upper airway obstruction, 
impaired pharyngeal function, muscle weakness and are at risk for aspiration. 
(10, 12, 13, 18) The financial implications of prolonged hospital stay and 
delayed recovery can be exorbitant (7). 
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1.2 Problem statement     
 
Anaesthetists use NDMRs every day. Practices’ regarding the use of 
neuromuscular blocking agents and their subsequent reversal, or lack thereof, 
differs among anaesthetists.  Common practice in South Africa aimed at 
identifying residual paralysis is primarily a clinical evaluation (for example: 
head lift for five consecutive seconds or the ability to cough) (19). Clinical 
assessment has been shown to over estimate neuromuscular recovery. As a 
result a high percentage of patients who receive NDMRs may present to the 
recovery room with residual paralysis. (18)  
 
The failure to prevent, recognise and manage PORC, compromises patient 
safety and is considered malpractice (10). The occurrence of PORC in the 
operating theatre recovery room of Chris Hani Baragwanath Academic 
hospital (CHBAH) is currently unknown. 
 
1.3 Aim of the study 
 
Aim of the study was to describe the occurrence of PORC in the recovery 
room in patients who have received intermediate acting NDMRs 
intraoperatively at CHBAH. 
 
1.4 Objectives of the study  
 
The primary objectives of the study were to:  
• document if the TOF ratio was done before administration of an 
anticholinesterase and extubation by the attending anaesthesiologist 
• describe the clinical assessment of neuromuscular function 
• describe the occurrence of PORC as determined by the TOF ratio 
• describe the occurrence of factors contributing to PORC (hypothermia, 
NDMR, patients age and the use of an anticholinesterase). 
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The secondary objectives were to: 
• compare with TOF ratio with the following clinical parameters: 
• saturation 
• handgrip 
• ability to cough 
• headlift 
• compare factors contributing to PORC (hypothermia, NDMR, patients 
age and the use of an anticholinesterase) with the TOF ratio. 
 
1.5 Research assumptions 
 
The following definitions were used in this study. 
 
Adult: a patient of the age 18 years and older. 
 
TOF: train of four ratio, a supramaximal stimulus of 50 mA and a frequency of 
2Hz is applied every 0.5 seconds over a 2 second interval (20). In this study, 
the TOF ratio will be measured using the ulnar nerve and assessing the 
adductor pollicis muscle with an accelerometer. 
 
PORC: is postoperative residual curarisation which is the presence of 
clinically significant paralysis postoperatively after using a neuromuscular 
blocking agent (21). In this study a TOF ratio of between 0.0 to 0.89 will be 
regarded as PORC. 
 
Hypothermia: core body temperature < 35 ° C (22). 
 
Adequate clinical reversal: headlift > 5 seconds, handgrip > 5 seconds, 
oxygen saturation > 90% and having the ability to cough 
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1.6 Demarcation of the study field 
 
The study took place in the operating theatre recovery room at CHBAH. 
CHBAH is a 2888 bed central hospital located in Soweto in Johannesburg, 
Gauteng. It is affiliated to the University of the Witwatersrand and is the 
referral centre for a number of smaller regional hospitals. The hospital has 25 
theatres and approximately 65 000 surgeries are done annually. 
 
1.7 Ethical considerations 
 
Approvals from the relevant authorities were obtained. 
 
Patients were invited to participate in the study the day before surgery. An 
introduction and detailed explanation including a patient information letter was 
given to the patient. Informed written consent was obtained from all study 
patients.  
 
The study was conducted in accordance with the Declaration of Helsinki (23) 
and the South African Good Clinical practice guidelines (24). 
 
1.8 Research methodology 
 
1.8.1 Research design 
 
A prospective, contextual and descriptive research design was used. 
1.8.2 Study population 
 
The study population included ASA 1 to 3 patients who had undergone 
elective surgery and received an intermediate acting NDMR. 
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1.8.3 Study sample 
 
In consultation with statistician a sample size of 55 patients was determined. 
A convenience sampling method was employed for this study.  
 
Inclusion criteria for this study were as follows: 
• adults 18 years and older 
• ASA 1 to 3 patients 
• surgery for an elective procedure 
• received an intermediate acting NDMR intraoperatively 
• extubated postoperatively. 
 
Exclusion criteria for this study were as follows: 
• patients who did not consent  
• no access to either ulnar nerve 
• patients who were unable to understand english. 
 
1.8.4 Data collection procedure 
 
On arrival to the operating theatre recovery room, once the anaesthetist 
responsible for the patient had signed the patient off as being adequately 
recovered, the TOF ratio was recorded by the researcher. 
 
The researcher used an accelerometer. Electrodes were placed over the ulnar 
nerve on the volar aspect of the wrist and the acceleration sensor was 
connected to an unrestricted thumb. Clinical assessment of neuromuscular 
function such as the ability to sustain a head lift, handgrip strength, the ability 
to cough, and pulse oximetry was carried out as these parameters are most 
commonly employed. Data was captured on a standardised data capture 
record. During the study period if a patient was found to have PORC, the 
researcher contacted the anaesthetist responsible for the patient and 
remained with the patient until the anaesthetist arrived. 
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1.8.5 Data analysis 
 
Data was captured using Microsoft Office Excel® data spread sheets. Data 
was analysed with the assistance of a biostatistician using STATISTICA, 
version 12.5. 
      
1.9 Significance of the study 
 
Surveys have shown that anaesthetist estimate the incidence of PORC to be 
1% or less and that more than 62% reported that they never use a monitor to 
assess neuromuscular function, 28% of the respondents to the survey 
reported using neuromuscular monitoring occasionally and only 9.7% used it 
routinely. (6, 12) 
 
In the literature the incidence of PORC ranges from 17 to 64%. The 
complications of PORC are significant and have a negative impact on 
morbidity and mortality and thus patient safety. Complications from PORC 
include hypoxia, upper airway obstruction, impaired pharyngeal function, 
muscle weakness and the risk of aspiration. Delays in leaving the recovery 
room have significant cost implications. (10, 18) 
 
The financial implications of prolonged hospital stay and delayed recovery can 
be exorbitant. The failure to prevent, recognise and manage PORC, 
compromises patient safety and is considered malpractice. (10) 
 
The study is significant as it could potentially contribute to changing practice 
and improving patient safety resulting in better outcomes for postoperative 
patients at CHBAH. 
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1.10 Validity and reliability of the study 
 
Measures were taken to ensure validity and reliability of this study. 
 
1.11 Study Outline 
 
The following chapters are presented in this study: 
• Chapter 1: Overview of the study 
• Chapter 2: Literature review 
• Chapter 3: Research design and methodology 
• Chapter 4: Results and discussion 
• Chapter 5: Summary, limitations, recommendations and conclusion. 
 
1.12 Summary  
 
This chapter provided a brief overview and summary regarding this research 
report. Topics covered included introduction and background, problem 
statement, aims and objectives, research assumptions, demarcation of the 
study field, ethical considerations, research methodology, significance of the 
study, validity and reliability and a study outline.  
 
The literature review is presented in the following chapter. 
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Chapter 2: Literature review 
 
In this chapter, various concepts of neuromuscular blocking agents and 
PORC are reviewed from the literature. In the first section, a brief overview on 
the history and pharmacology of the neuromuscular blocking agents is 
presented. Thereafter, PORC will be discussed in detail. The testing of 
neuromuscular function to identify PORC will be discussed. Risk factors for 
the development of PORC are examined next. Important principles regarding 
the prevention of PORC will then be evaluated. In the following section the 
consequences of PORC on patient`s quality of life and functioning will be 
addressed. The prevalence of PORC according to various international 
studies will be considered. 
 
2.1 Background 
 
Anaesthesia produces a reversible loss of consciousness. “It is characterised 
by hypnosis, analgesia, amnesia, immobility, ensuring haemodynamic 
stability, and reducing the stress response”. Immobility is usually achieved 
with lower levels of anaesthesia by the co-administration of curare type 
neuromuscular blocking agent. Neuromuscular blockade plays an important 
role in providing adequate operating conditions. (25) 
 
2.2 Neuromuscular blocking agents 
 
2.2.1 History 
 
Neuromuscular blocking agents have been described since the sixteenth 
century when European explorers noticed that the indigenous population in 
the Amazon killed their prey by paralysing them using the sap of the rubber 
plant Chondrodendron tomentosum (1). Curare was introduced into 
anaesthesia in 1942, in Montreal Canada, by Griffith and Johnson (26, 27). 
The first clinical use of curare (intocostrin) was on a patient undergoing an 
  11 
appendectomy (27). Initial recommendations advocating the use of an 
anticholinesterase (e.g. pyridostigmine) to antagonise the residual block was “ 
when clinically indicated” (28).  
 
It was in the mid 1950s that the use of an anticholinesterase became routine 
because of the increasing numbers of inadequate recoveries, postoperatively 
(28). A retrospective study by Beech and Todd (28, 29) in 1954 revealed that 
the anaesthetic mortality rate was six times greater when a neuromuscular 
blocking agent was utilised. In this study the major cause of death with the 
use of curare was cited as cardiac arrest, which occurred within 10 minutes of 
administration. The average dose of suxamethonium was 197mg which is 
higher than current dosing practices- this may be the cause of cardiac arrest.  
Prior to the use of curare the only way to achieve adequate relaxation was the 
use of deep inhalational agents which were poorly tolerated by elderly and ill 
patients with an ASA score greater than three (26). 
 
2.2.2 Classification 
 
Neuromuscular blocking agents consist of two major groups recognised by 
their mechanism of action: depolarising and non depolarising. Depolarising 
muscle relaxants e.g. suxamethonium, exert their effects by binding to the 
acetylcholine receptors on the motor end plate. This results in the 
depolarisation of the motor end plate. It also prevents repolarisation and thus 
further depolarisation. NDMRs competitively occupy receptors on the motor 
end plate, thereby preventing acetylcholine from binding to the receptors. (9, 
30).  
 
Under normal physiological conditions only a fraction of the available 
receptors are needed to generate a muscular contraction. There is no 
detectable block until 75 to 80 % of receptors are occupies. To produce 
complete block i.e. complete paralysis, approximately 90 to 95 % of receptors 
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must be occupied. Therefore adequate muscle relaxation corresponds to a 
narrow range of 85 to 90% receptor occupancy. (30, 31) 
NDMR’s can be further sub classified according to their molecular structure 
(benzylisoquinolones and aminosteroids) as seen in Table 2.1 or according to 
their duration of action (short, intermediate and long acting) as shown in Table 
2.2.  Controversy over cisatracurium exists. Cisatracurium may be considered 
an intermediate-acting muscle relaxant but this is only if twice the ED 95 is 
given. However, if the recommended intubation dose of cisatracurium (i.e. 3 × 
ED 95) is routinely used, cisatracurium will then be classified as a long-acting 
agent (i.e. clinical duration > 60 min) with a potential influence on the 
development of respiratory complications. (9, 32) 
 
Table 2.1 Classification of neuromuscular blocking agents according to 
molecular structure (9) 
 
Depolarising  
            
                         Non depolarising 
 Aminosteroids Benzylisoquinolones 
 
Suxamethonium 
Rocuronium 
Vecuronium 
Pancuronium 
 
Atracurium 
Cisatracurium 
Mivacurium 
Doxacurium 
Alcuronium 
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Table 2.2 Classification of NDMR according to duration of action (9). 
 
2.2.3 Advantages of muscle relaxants 
 
Griffith et al (28) published a case series approximately 70 years ago on the 
use of non depolarising agents in abdominal surgery and stated: 
“It seems to us, as the result of these preliminary clinical  
investigations, that the curare may prove to be a drug that will 
occasionally be of great value, and will give us a means of  
providing the surgeon rapidly with excellent muscle  
relaxation at critical  times during certain operations”. 
 
Neuromuscular blocking agents facilitate endotracheal intubation, provide 
optimal operating conditions and produce adequate circumstances for 
ventilation. They permit the current practice of balanced anaesthesia: 
analgesia, hypnosis and muscle relaxation with fewer side effects on the 
cardiovascular and respiratory systems. Prior to the introduction of 
neuromuscular blockers, muscle relaxation was achieved using a deep 
anaesthetic technique. This resulted in the majority of patients developing 
hypotension, arrhythmias, hypoxia, laryngospasms and bronchospasm. (26, 
30) 
 
Endotracheal intubation and some surgeries, require an intense 
neuromuscular blockade to prevent movement. Examples where any 
movement during surgery could be detrimental include neurosurgical, 
 
Short acting 
 
Intermediate acting 
 
Long acting 
Mivacurium Atracurium 
Rocuronium 
Vecuronium 
Cisatracurium 
Pancuronium 
Alcuronium 
Doxacurium 
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ophthalmic and cardiothoracic procedures (33). There should be no response 
to TOF ratio when an intense blockade is required (15, 34).  
 
2.2.4 Disadvantages of muscle relaxants 
 
Specific complications are based on individual classes of drugs. 
Suxamethonium is a depolarising muscle relaxant and is well known for its 
complications, which include malignant hyperthermia, scoline apnoea, 
bradycardia, hyperkalaemia and muscle pain. The NDMRs have side effects 
that are agent specific e.g. pancuronium causes tachycardia and hypertension 
and atracurium stimulates histamine release and is associated with 
anaphylactoid and anaphylactic reactions. (9, 30) 
 
Neuromuscular blocking agents have no analgesic or anaesthetic activity and 
therefore an ineffectual anaesthetic technique can result in intraoperative 
awareness. This predisposes patients to developing posttraumatic stress 
disorder. The use of a neuromuscular blocking agent in an unanticipated 
difficult airway can result in brain injury and even death (26). Failure to 
intubate and ventilate when a NDMR has been given will result in the patient 
not being ventilated and as a consequence the patient becomes hypoxic 
resulting in hypoxic brain injury or death. (35, 36) 
 
Inappropriate use of neuromuscular blocking agents can result in residual 
paralysis in the postoperative period and is associated with a number of 
complications that will be discussed in more detail later in the chapter. 
 
2.2.5 Neuromuscular blocking antagonists 
 
Complete neuromuscular function post surgery is desirable unless 
postoperative ventilation is deemed necessary (8). Anticholinesterases are 
agents administered to increase the concentration of acetylcholine at the 
neuromuscular junction (9, 17). The increase in acetylcholine results in the 
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competitive antagonism of NDMR at the neuromuscular junction (35). It can 
only be used for NDMR and is not to be used for the depolarising agent 
suxamethonium, as it has the opposite effect with suxamethonium i.e. 
enhances the neuromuscular block (1). The anticholinesterases are 
administered with an anticholinergic (e.g. glycopyrolate or atropine) to prevent 
the side effects associated with the activation of muscarinic receptors. Due to 
the limited availability of edrophonium in South Africa and the long onset time 
for pyridostigmine, neostigmine is the primary anticholinesterase used. The 
preferred anticholinergic is glycopyrolate as it does not cross the blood brain 
barrier. (9) 
 
Side effects encountered with the use of neostigmine include arrhythmias, dry 
mouth, nausea and vomiting, bronchospasm, severe bradycardia and 
asystole (18). It has also been reported that neostigmine increases 
intraluminal pressure in the bowel and can compromise intestinal 
anastomoses (28).  
 
Patients with complete recovery (TOF ratio ≥ 0.9) from NDMR do not require 
reversal. Complete recovery can only be assessed with TOF ratio and not 
with clinical parameters. Clinical parameters are not accurate in identifying the 
presence of recovery. (18) 
 
Before an anticholinesterase (e.g. neostigmine) is administered the 
anaesthetist has to identify whether spontaneous recovery is sufficient to 
allow reversal. The effectiveness of anticholinesterase administration is 
directly dependant on the degree of spontaneous recovery. (26) Objective 
assessment of recovery can be performed by using an accelerometer to 
assess the TOF ratio (5, 33). The result obtained can be used to calculate the 
dosage of anticholinesterase needed to successfully reverse neuromuscular 
block consequently reducing the probability of side effects (37).  Complete 
recovery is defined as a TOF ratio of 1, therefore if a patient has a TOF ratio 
of 0.7 the amount of antagonist needed to achieve a TOF ratio of 1 will be 
less then that needed by a patient with a TOF ratio of 0.3. (18, 34) 
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An antagonist is administered to reduce PORC, however a study conducted in 
Portugal (2013) found a 15% higher incidence of PORC in patients who had 
received a reversal agent. No neuromuscular monitoring was utilized to 
determine how much antagonist was actually needed. This study does not 
mention when the antagonist was administered in relation to spontaneous 
recovery. (37)  
 
Neostigmine has a ceiling effect and as a result it is unable to reverse 
profound blockade as it increases the concentration of acetylcholine but has 
no direct effects on the NDMR’s.  The maximum dosage of neostigmine is 60 
to 80 mcg/kg and above this further increases in anticholinesterase will not 
produce greater antagonism. Increasing the concentration of acetylcholine at 
the neuromuscular junction will only improve neuromuscular function if 
approximately 20% of receptors are not bound to a NDMR’s, therefore with 
profound blockade where 100% of the receptors are occupied, neostigmine 
will have no effect. (1)   
 
Time constraints and pressure on the anaesthetist to wake a patient up 
instantaneously after surgery often results in neostigmine being administered 
too early resulting in PORC (21, 38). Additionally, administering reversal when 
adequate recovery is present can result in muscle spasm. Increasing 
acetylcholine at the neuromuscular junction in the absence NDMR presence 
will result in excessive motor end plate depolarisation. These spasms can 
also cause muscle weakness in the postoperative period with a normal TOF 
ratio. (18, 33) 
 
Sugammadex is a new reversal agent that has recently become available in 
South Africa and is expected to change current anaesthetic practice and 
therefore will be discussed in greater detail. (21, 39) 
 
Sugammadex is a modified γ cyclodextrin, which are cyclic oligosaccharide 
carbohydrates. They have a ring structure with a hydrophilic surface 
facilitating its solubility in water. It retains the ability to bind to complex 
hydrophobic molecules within its central core. The nominated γ means that it 
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contains eight glucose units. (39) It is the leading selective relaxant binding 
agent indicated to antagonise the neuromuscular blockade of aminosteroidal 
NDMR’s induced during general anesthesia.(1).  
 
The reason for its lack of affinity towards the benzylisoquinolones is owing to 
the size of its inner cavity and its structural design for the correct hydrophobic 
steroidal skeleton. The affinity for other steroidal drugs like cortisone, 
hydrocortisone and aldosterone to sugammadex is 140 times less than that of 
rocuronium. Drugs identified as having the ability to displace rocuronium and 
vecuronium from sugammadex are toremifene and flucloxacillin. (40) 
 
A prompt reversal of profound neuromuscular blockade is needed in an 
emergency situation as in a “cannot intubate, cannot ventilate” scenario.  In 
these circumstances the use of an anticholinesterase is contraindicated, as it 
has no effect in reversing profound blockades. Based on studies on human 
volunteers reversal of profound blockade can be achieved using higher 
dosages of sugammadex. (38, 39) Doses of 16 mg/kg are recommended for 
reversing an intense block (no twitch on TOF count) and complete reversal is 
achieved in less than three minutes. Recovery using sugammadex is 
consequently faster than spontaneous recovery from suxamethonium. (40) 
 
The molecular weight of sugammadex is 2178. It has an osmolality ranging 
between 300 and 500 mOsmol/kg and a pH of 7.5. The blood brain barrier 
penetration (< 3 %) and placental transfer (< 6%) are considered nominal. 
Protein binding is low. (1) Sugammadex rapidly encapsulates free 
aminosteroidal NDMRs, forming a stable and inactive complex which prevents 
the pharmacological action of the aminosteroidal NDMRs at the 
neuromuscular junction (39). This produces a diffusion gradient between 
concentrations in the plasma and in the tissues. NDMRs from the tissue thus 
enter the plasma and are encapsulated by sugammadex even further.  It 
binds to rocuronium with a high affinity and with a slightly lower affinity to 
vecuronium. (40) 
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The encapsulated complex is excreted by the kidney. It is alleged to have no 
intrinsic activity and has no direct effects on cholinergic transmission. (38, 40) 
Teratogenicity or genotoxicity has not been demonstrated in animals. 
Sugammadex produces a faster and more predictable recovery compared to 
neostigmine. The ability to efficiently and rapidly reverse very deep levels of 
neuromuscular blockade provides an advantage over neostigmine. 
Inhalational agents, which ordinarily prolong recovery times, do not influence 
the efficacy of sugammadex. (40, 41) 
  
The majority of side effects observed in the phase II and III studies were 
nonspecific, including nausea, hypotension, coughing, movement and a dry 
mouth. The incidence of a prolonged QT interval was identified to be 
comparable to the placebo group. A prolonged QT interval is observed with 
several agents used in anesthesiology therefore its significance is uncertain. 
(40, 41) Sugammadex has been used in the management of rocuronium 
induced anaphylaxis, however there are case studies of sugammadex also 
causing allergic reactions (40, 42). Hypersensitivity reactions have caused 
delays in obtaining FDA approval in the United States of America (42). The 
manufacturer of sugammadex recommends that special caution be exercised 
when using sugammadex in patients with decreased hepatic and renal 
function and in obstetric patients. Sugammadex is a new drug and limited 
studies have been done on a variety of patients to accurately determine its 
side effect profile. (27, 38) 
 
Dose recommendations of sugammadex depend on the intensity of blockade. 
The presence of four twitches requires 2 mg/kg, two twitches 4 mg/kg and 
with the absence of twitches up to 16 mg/kg (38, 43). As is evident by the 
dosing protocols, the depth of neuromuscular block has to be assessed or an 
inappropriate dose of sugammadex could be administered which would cause 
a residual block or recurarisation following the administration sugammadex. 
There is an economic barrier to the wide introduction of sugammadex in 
South Africa. Further trials considering the cost-effectiveness should therefore 
be conducted. (11, 21, 43) 
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2.3 Post operative residual curarisation 
 
2.3.1 Definition of PORC 
 
PORC is defined as the presence of persistent paralysis after emergence 
from general anaesthesia with neuromuscular blocking drugs especially the 
NDMRs. The first definition of PORC was set at a TOF ratio < 0.7, this has 
now been changed to TOF ratio < 0.9, as it has been shown that residual 
paralysis above 0.7 is problematic and produces a number of complications 
(21).  
 
2.3.2 Testing of neuromuscular function 
 
Clinical assessment of residual paralysis comprising of head lift of 5 to 10 
seconds, five second handgrip, adequate minute ventilation and negative 
inspiratory pressures greater than -30 cmH2O, is still used by clinicians as 
indicators of adequate muscle function recovery (7, 12).  The evaluation of a 
muscular response to an electrical stimulus is considered more sensitive and 
specific for an accurate assessment. Table 2.3 explains the modes of 
stimulation that can be used including tetanic, post tetanic, double burst and 
TOF ratio stimulation. (44)  
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Table 2.3 Modes of neuromuscular stimulation (44, 45). 
 
Type of 
stimulation 
 
Frequency 
used 
 
Duration 
 
Indication 
 
Single twitch 
 
0.1 Hz 
 
0.2 sec 
 
Induction 
 
Tetanus 
 
50 Hz 
 
5 sec 
 
No clinical use 
 
Post tetanic 
count 
 
50 Hz 
 
2 sec 
 
Intense block 
 
Double burst  
 
50 Hz 
 
40 msec 
Residual 
curarisation 
 
TOF 
 
2 Hz 
 
2 sec 
Intraoperative and 
postoperative 
 
 
The TOF ratio is the most frequently used mode of nerve stimulation. A 
supramaximal stimulus of 50 mA and a frequency of 2 Hz is applied every 0.5 
seconds over a two second interval (46). This is repeated every 10 to 15 
seconds. The effect detected is known as the TOF count or ratio. TOF count 
is the number of twitches observed after stimulation. A count of four is 
required before reversal can be administered. (43, 47, 48) The TOF ratio 
divides the amplitude of the fourth response by the amplitude to the first 
response (fade) i.e.  
TOF ratio = T4 . 
                                                                     T1 
 
In a patient that has not received any NDMR, the TOF ratio should be 1, the 
height of the first and the fourth twitch being the same. If a depolarising 
muscle relaxant is used, (e.g. suxamethonium) the amplitude of all four 
twitches is decreased but the TOF ratio is still 1 as the first and fourth twitch 
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are of equal height, unless a phase two block develops resulting in the 
development of fade. This is illustrated in Figure 2.1.  
 
 
Figure 2.1 TOF ratio differences between depolarising and NDMR (49). 
 
NDMR reduce the TOF ratio and the reduction is inversely proportional to the 
degree of paralysis. The number of elicited twitches indicates the degree of 
receptor occupancy. Disappearance of T4, T3, T2, T1 corresponds to 75%, 
80%, 90% and 100% occupancy.  Therefore even with a TOF ratio > 0.9 70 % 
of receptors may still be occupied. (5, 15, 48)  Figure 2.2 below illustrates the 
TOF ratio response pattern of NDMRs. 
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Figure 2.2 TOF ratio response pattern (50). 
 
Advantages of using TOF ratio as compared to the other modes of stimulation 
include that a control value does not need to be recorded for an accurate 
assessment of residual block, unlike a single twitch where a control twitch is 
needed for comparison. It is also less painful than tetanic stimulation for a 
post tetanic count and can be used in an awake patient. Bailliard et al (51) 
found that 3.5% of the patients sampled remembered the use of the TOF ratio 
in the recovery room and that the degree of discomfort scored < 3 on the 
Visual Analogue Pain Scale. An additional advantage is that monitoring can 
be performed frequently unlike tetanic stimulation, which eventually produces 
an exaggerated and inaccurate response. (15) 
 
The most prevalent site of nerve stimulation is the ulnar nerve and the 
adductor pollicis is assessed for a response. The choice of nerve used needs 
to fulfil certain criteria. It must have a motor element, it must be close to the 
skin and lastly the muscular contraction elicited must be visible. Optimal 
stimulation requires that the electrodes be applied on the volar side of the 
wrist. The negative electrode is placed 1 cm proximal to the point at which the 
proximal flexion crease of the wrist crosses the flexor carpi ulnaris tendon. 
The positive electrode is placed 2 to 3 cm proximal to the negative electrode. 
When the adductor pollicis cannot be assessed the facial nerve is stimulated 
and motor responses in the corrugator supercilli is utilised instead.(15) 
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Different muscles have different sensitivity profiles to neuromuscular blocking 
agents. The diaphragm is the least sensitive and therefore recovers the 
fastest from blockade while the adductor pollicis is one of the last muscles to 
recover (16). To accurately assess laryngeal muscle recovery the most 
accurate muscles to assess are the orbicularis oculi or corrugator supercilli 
(muscles around the eye) as they have a similar sensitivity profile to the 
laryngeal muscles. The reason for the difference in sensitivity profile is largely 
unknown with possible reasons including different muscle fibres, blood supply, 
innervation and muscle temperature. (15) 
 
Kopman et al (18) demonstrated that the clinical parameters  stated 
previously correlate with a TOF ratio of between 0.4 and 0.8. Tactile or visual 
assessment of the TOF ratio is no longer considered acceptable as it can 
simply detect residual paralysis of a TOF ratio of < 0.4. Objective and 
quantitative measurements are required to increase the sensitivity of this test 
in identifying residual paralysis. (26) 
 
Neuromuscular monitoring in the clinical setting can be performed with a 
mechanomyography (isometric contractions measured), electromyography 
(measures compound action potentials) and with an acceleromyography 
(measures acceleration). Acceleromyography uses Newton’s second law of 
motion i.e.  
force = mass × acceleration. 
Mass is constant therefore force is directly proportional to the acceleration. 
(14) Figure 2.3 illustrates an accelerometer (TOF Watch) commonly used in 
clinical practice. The gold standard currently is the mechanomyography, 
however its heavy weight prevents its use routinely in clinical practice. A study 
by Viby-Mogensen and Claudius (4) in 2008 proposed that 
acceleromyography is as useful as mechanomyography (grade B evidence). 
They did suggest that the TOF ratio should be 0.9 or even higher to exclude 
PORC (4). 
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Figure 2.3 TOF Watch® stimulating the ulnar nerve. TOF ratio=0.69 (50). 
 
There is conflicting evidence regarding the effectiveness of intraoperative 
neuromuscular monitoring in reducing PORC (11). Despite the conflicting data 
a TOF ratio initially set at 0.7, but now agreed at 0.9, is considered to 
correlate with sufficient clinical recovery of muscle function (26). Residual 
paralysis cannot be prevented by neuromuscular monitoring but it does alert 
the anaesthetist to the problem so that appropriate management can be 
applied, e.g. delay reversal until four twitches are present and extubate only 
when TOF ratio > 0.8. It can also guide the anaesthetist as to how much 
reversal should be given taking into account the ceiling dose of neostigmine. 
(21, 46) 
 
A TOF ratio of > 0.9 does not mean that all the acetylcholine receptors are 
available for potentiating an action potential. However there are now enough 
receptors to facilitate adequate muscular function.  A study by Baumuller et.al 
(52) found that the administration of  sugamaddex, after a TOF ratio of > 0.9 
was established, did not produce any clinical difference in neuromuscular 
recovery.  
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2.3.3 Risk factors for PORC 
 
Patients who receive multiple boluses or a continuous infusion of NDMRs are 
at a higher risk of PORC. The risk is higher because larger cumulative doses 
of the NMDA’s are administered over a short period as compared to a single 
appropriately calculated dose when a bolus dose regime is used. The 
incidence is thought to be higher in patients with organ dysfunction as this 
alters the pharmacokinetic properties of the drug.(7, 25) Dosing of NDMR’s is 
according to the ideal body weight and therefore obese patients may also 
present with an increase risk of developing PORC if the total body weight is 
used (9). 
 
Hypothermia has also been shown to lengthen the duration of action of the 
NDMRs as their metabolism is reduced with decreasing temperatures. Core 
temperatures < 36°C result in a decrease in blood viscosity and thus a 
decrease in blood flow. In addition enzymatic function is slower at lower 
temperatures. (26, 30, 53) 
 
Heier et al (54) found that the clearance of vecuronium decreased by 10% for 
every 1°C  drop in  core body temperature. A core body temperatures below 
32°C is associated with an increased potency of NDMR’s however these 
temperatures are rarely encountered in routine surgery.  
 
Ageing is accompanied by numerous physiological changes including a 
decrease in renal and hepatic blood flow resulting in a decline of function. 
This has an impact on the pharmacodynamics and pharmacokinetics of 
NDMR’s in the elderly population. Ageing is also associated with anatomical 
changes such as a reduction in the number of motor neurons in the spinal 
cord, a loss of muscle fibres and a decrease in the size of type two muscle 
fibres. However the difference in the pharmacological behaviour of NDMRs 
has been demonstrated to be primarily from the physiological changes (55). 
Pietraszewski et.al (32) found that 90% of all elderly patients (> 65years) had 
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residual paralysis when neuromuscular monitoring was not used. Elderly 
patients were twice as likely to develop residual paralysis when compared to 
younger patients. 
 
Magnesium is frequently used in anaesthesia to prevent hypertension and 
arrhythmias and is occasionally used as a bronchodilator. Magnesium also 
potentiates the effects of NDMRs by the antagonism of calcium at the 
presynaptic terminal of the neuromuscular junction, reducing the release of 
acetylcholinesterase. (9, 56, 57)  
 
Pinard et al (56) found that administration of magnesium  in patients 
undergoing cardiac surgery resulted in a increase in the duration of 
neuromuscular blockade of cisatracurium by 30 to 35 minutes. A study at the 
University of Cape Town found administering magnesium to rats after an 
anaesthetic, during which rocuronium was used, decreased the TOF ratio by 
52.5% to 19.4% despite apparent full neuromuscular recovery (TOF ratio 
>0.9). The use of magnesium resulted in recurarisation (58). 
 
The increasing pressure for quick turnover of surgical cases may also shorten 
the time between the administration of reversal and endotracheal extubation. 
The current practice of extubating five minutes after administering an 
anticholinesterase is a potentially unsafe practice as insufficient time has 
passed for the adequate return of neuromuscular function. (7)  
 
In addition some anaesthetists do not routinely administer an 
anticholinesterase if spontaneous ventilation with adequate tidal volumes (6 
ml/kg) develops before the end of surgery (12, 59). This predisposes to the 
development of PORC as adequate tidal volumes are achieved with a TOF 
ratio < 0.4 (12, 21). 
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2.3.4 Prevention of PORC 
 
Four steps are supported to prevent PORC: avoid long acting NDMRs, 
prevent hypothermia as it delays recovery, anticholinesterase administration 
only after spontaneous recovery is identified by the presence of four visible 
twitches on the TOF ratio and reversal should be administered in any patient 
with a TOF ratio < 0.9 (16, 26). 
 
Neuromuscular blocking agents should be avoided unless absolutely 
necessary (60). Patients with co-morbid illnesses need drug dose titration to 
effect, as the pharmacokinetic and pharmacodynamics properties of the 
NDMRs are often altered (6). NDMR drug selection should be determined 
according to the duration of surgery and the patient’s pharmacokinetic profile. 
 
Avoid repeated boluses, particularly towards the end of surgery. 
Neuromuscular monitoring should guide both intraoperative and postoperative 
assessments of muscle function (53). Delay extubation and reversal in 
patients with intense blockades until spontaneous recovery is evident. It 
should be noted that spontaneous recovery does not mean that there is no 
residual paralysis as different muscle groups recover at different rates from 
NDMR. In some countries, it is a common practice not to give reversal if there 
is spontaneous recovery. This is considered bad practice and affects patient 
safety. Reversal should only be omitted when objective assessments using an 
acceleromyograph or mechanomyograph is used and a TOF ratio ≥ 0.9 is 
found. (60) 
 
2.3.5 Complications of PORC 
 
Murphy et al (59) identified numerous side effects of PORC including a higher 
risk of aspiration, upper airway obstruction, depressed hypoxic drive, 
subjective muscle weakness and pharyngeal muscle weakness with impaired 
swallowing. 
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A review by Ghai et al (15) concluded that there is a good correlation between 
the clinical observation and TOF ratio but the relationship between TOF ratio 
and the signs and symptoms of PORC differs among patients Table 2.4 
categorises which signs are found at a specific TOF. 
 
Table 2.4 TOF ratio associated with specific clinical signs. (7, 12, 15) 
 
 
As a result of PORC, there are delays in discharge from the operating theatre 
recovery room. A study by Butterly et.al (61) found that patients with PORC 
(TOF ratio < 0.9) had a mean operating theatre recovery room length of stay 
of 323 minutes compared to those without PORC who stayed on average 
about 243 minutes. Although in their study the length of stay in the recovery 
room was particularly long, it does demonstrate that the presence of PORC 
delays discharge from the operating theatre recovery room. This has 
 
TOF 
                
Signs and symptoms 
 
TOF ratio < 0.4 
Inability to lift head or arm 
Tidal volume can be normal 
Vital capacity and negative inspiratory 
pressures are decreased 
 
TOF ratio < 0.6 
Head lift for three seconds 
Eyes open wide 
Able to stick out tongue 
Vital capacity and negative inspiratory 
pressures are reduced 
 
TOF  ratio < 0.8 
Head lift for five seconds 
Grip strength 60% of normal 
Vital capacity and negative inspiratory 
pressures are normal 
Diplopia or facial weakness 
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significant economic consequences as the operating theatre recovery room 
can be fully occupied preventing further admissions. (61) 
 
Profound muscle weakness produces anxiety in the majority of patients, this 
can have long term psychological effects including depression and post 
traumatic stress disorder (10). Patients in recovery will often complain of 
“feeling weak” or “difficulty seeing or speaking” as a consequence of diplopia 
and weakness of the oral cavity muscles (18, 19). 
 
Murphy et al (59) performed a study focused on patients subjective 
experiences compared to the TOF ratio. Patients complained of general 
weakness, difficulty in opening eyes and lifting head, difficulty in tracking 
objects, blurry vision, difficulty in speaking and muscle weakness. Results of 
the study showed that 54 to 91% of patients with a TOF ratio < 0.9 
complained of the above symptoms, compared to 9 to 45% of patients in the 
TOF ratio ≥ 0.9 group. The possible causes of muscle weakness in the group 
with a TOF ratio ≥ 0.9 include residual effects of inhalational agents, 
hypothermia, electrolyte imbalances, prolonged immobility and an 
inflammatory response to perioperative stressors. The clinical evaluation of 
PORC is often difficult because of the effects of intraoperative anaesthetic 
drugs, shivering, analgesia and pain. The multifactorial aetiology of muscle 
weakness presents a limitation to the above study.  
 
A study performed in Germany in 2006 by Eikermann et al (62) induced a 
partial neurological blockade (TOF ratio between 0.5 to 0.8) in 10 healthy 
young males volunteers. The volunteers were kept spontaneously breathing. 
An MRI was performed to identify the upper airway dimensions; 
electromyography was used to measure the force of contractions of the 
genioglossus muscle and spirometry was used to measure lung volumes. 
These tests were all performed on different days. Results from this study 
showed a 10 to 20% decrease in inspiratory volumes and an increase in the 
anterior posterior upper airway diameter during forced inspiration. A decrease 
in genioglossus activity was also identified. There were no effects on lung 
volumes and upper airway size during expiration, which is expected, as 
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expiration is primarily a passive movement. This study suggests that a 
residual block that does not produce respiratory symptoms (e.g. desaturation) 
still results in impaired upper airway dimensions and function. (62, 63) 
 
The common of effects of PORC are usually seen 24 to 48 hours after 
surgery, these include atelectasis and pneumonia and are usually treated by 
surgeons. As a consequence many anaesthesiologists do not recognise that 
PORC continues to be a danger long after the patient has left theatre. (32, 64) 
 
2.3.6 Reported incidence of PORC 
 
One of the first studies looking at the incidence of PORC was done by Viby-
Mogensen et al (65) in 1979. All patients tested received a long acting NDMR. 
They used a TOF ratio of < 0.7 and found that 42% of patients had residual 
block despite having clinical recovery. (10) If the new criterion of a              
TOF ratio < 0.9 had been used the incidence would have been 72% (21).  
 
A study done in South Africa reported a 42.9% occurrence of PORC (TOF 
ratio < 0.9) in a hospital in Bloemfontein in 2004. These results are similar to 
those attained by Viby-Mogensen et al (65) 25 years earlier. (19) 
 
In 2011, a multicentre study in Portugal aimed at identifying the incidence of 
PORC, reported that 26% of patients presented to the recovery room with a 
TOF RATIO< 0.9, 66.6% had been given reversal. A higher incidence of 
residual paralysis was found in patients who had received reversal (30%) 
compared to those who had not (17%). It is postulated that the reason for this 
is that reversal is avoided by many because of its side effect profile, therefore 
when used it was possibly for rapid reversal. (37). 
 
Despite the use of intermediate acting NDMR’s and the use of reversal the 
estimated incidence or PORC ranges from 17 to 36% and can be as high as 
64% in some institutions (10, 12, 18). It has also been postulated that 
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approximately 40% of patients will develop at least one hypoxaemic episode 
in the recovery room and that these occur within the first 20 minutes after 
admission (64). Routine neuromuscular monitoring has been advocated as a 
means of reducing the incidence of PORC and therefore hypoxaemic 
episodes (16). 
 
Administration of neostigmine after surgery does not always ensure complete 
restoration of patient’s muscle strength. Neostigmine in the absence of a 
neuromuscular block (TOF ratio ≥ 0.9), will impair upper airway volumes, 
genioglossus muscle function and diaphragmatic function. A study by Grosse-
Sundrup (25) postulated that the administration of neostigmine in the absence 
of a residual block could lead to muscle weakness (acetylcholine 
accumulation at the motor end plate results in spasm). In light of this 
information, the need for intraoperative neuromuscular monitoring is further 
highlighted. (7, 25) 
 
A review article by Murphy et al (44) identified the majority of studies 
conducted from 1979 to 2013 have demonstrated that the incidence of PORC 
(using objective neuromuscular monitoring) remains high despite the 
introduction of intermediate acting NDMR. Most anaesthetists still believe that 
clinically significant muscle weakness is an infrequent event (44, 66).  
 
A survey conducted in 2011 indicated that anaesthetists estimated the 
incidence of PORC to be 1% or less. This survey was sent to American and 
European anaesthetists and 80% responded that they had never seen 
clinically significant residual paralysis. (12) 
 
Evidence suggests that PORC impairs clinical recovery and has a negative 
impact on patient safety. Clinical studies have shown through objective 
measures that a TOF ratio < 0.9 reduces upper airway volumes, causes 
airway obstruction, hypoxemic events and postoperative pulmonary 
complications. In light of the research done it has been recommended that 
neuromuscular monitoring be performed routinely to reduce the incidence of 
PORC and improve patient safety. (7, 53) Patient perceived quality of 
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recovery is an important measure of patient safety and research has shown 
that most patients will complain of uncomfortable symptoms of muscle 
weakness with a TOF ratio < 0.8 (44). Some authors have even advocated 
that the use of an acceleromyograph should become a standard of care 
similar to pulse oximetry (11, 28).  
 
The use of neuromuscular monitoring has been shown to reduce the 
incidence of PORC from between 38.1 to 67% (14). An assessment of 
practice found that the majority of anaesthetists do not use neuromuscular 
monitoring, either because they feel that clinical signs are adequate or 
because of a lack of equipment availability at some institutes (12). Tsai et al 
(67) concluded that neuromuscular monitoring is an evidence based practice, 
it is non invasive and has little risk. Their recommendation was that this 
measurement should be performed in theatre before extubation to ensure 
patient safety. 
 
2.4 Summary 
 
An in-depth discussion on various subjects has been presented in the 
literature review regarding NDMR and PORC. In the first section, a brief 
overview of the history and pharmacology of neuromuscular blocking agents 
was provided. Thereafter, PORC was discussed in detail. The testing of 
neuromuscular function to identify PORC was discussed. Risk factors for the 
development of PORC were examined next. Important principles regarding 
the prevention of PORC was then evaluated. The consequences of PORC on 
patient`s quality of life and functioning was addressed. The prevalence of 
PORC according to various international studies was considered. 
 
The following chapter deals with the research methodology of this study. 
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Chapter 3: Research methodology 
 
 
The problem statement, aim and objectives of the study, ethical 
considerations, research methodology and validity and reliability of the study 
are discussed in this chapter. 
  
3.1 Problem statement   
   
Anaesthetists use NDMRs every day. Practices’ regarding the use of 
neuromuscular blocking agents and their subsequent reversal, or lack thereof, 
differs among anaesthetists.  Common practice in South Africa aimed at 
identifying residual paralysis is primarily a clinical evaluation (for example: 
head lift for five consecutive seconds or the ability to cough) (19). Clinical 
assessment has been shown to over estimate neuromuscular recovery. As a 
result a high percentage of patients who receive NDMRs may present to the 
recovery room with residual paralysis. (18)  
 
The failure to prevent, recognise and manage PORC, compromises patient 
safety and is considered malpractice. (10) The occurrence of PORC in the 
operating theatre recovery room of Chris Hani Baragwanath Academic 
hospital (CHBAH) is currently unknown. 
 
3.2 Aim of the study 
 
Aim of the study was to describe the occurrence of PORC in the recovery 
room in patients who have received intermediate acting NDMRs 
intraoperatively at CHBAH. 
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3.3 Objectives of the study 
 
The primary objectives of the study were to:  
• document if the TOF ratio was done before administration of an 
anticholinesterase and extubation by the attending anaesthesiologist 
• describe the clinical assessment of neuromuscular function 
• describe the occurrence of PORC as determined by the TOF ratio 
• describe the occurrence of factors contributing to PORC (hypothermia, 
NDMR, patients age and the use of an anticholinesterase). 
The secondary objectives were to: 
• compare with TOF ratio with the following clinical parameters: 
o saturation 
o handgrip 
o ability to cough 
o headlift 
• compare factors contributing to PORC (hypothermia, NDMR, patients 
age and the use of an anticholinesterase) with the TOF ratio. 
 
3.4 Ethical considerations 
 
Approval to conduct the study was obtained from the Human Research Ethics 
Committee (Medical) (Appendix 1) and the Post Graduate Committee of the 
University of Witwatersrand (Appendix 2). Permission from the Medical 
Advisory Committee of CHBAH was also acquired. (Appendix 3) 
 
Patients were invited to participate in the study the day before surgery. An 
introduction and detailed explanation including a patient information letter 
(Appendix 4) was given to the patient. Informed written consent (Appendix 5) 
was obtained from all study patients who agreed to take part. The patient 
information letter and informed consent was written in a manner that was 
clear to the intended patients.  
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During the study period if a patient was found to have PORC, the researcher 
contacted the anaesthetist responsible for the patient and remained with the 
patient until the anaesthetist arrived. 
 
All information regarding individual participants was recorded anonymously 
and kept confidential. Records will be stored in a secure place for six years. 
 
The study was conducted in accordance with the Declaration of Helsinki (23) 
and the South African Good Clinical practice guidelines (24). 
 
3.5 Research methodology 
 
3.5.1 Research design 
 
A research design determines what methods are used find subjects, collect 
and analyse data, and interpret results. It can therefore be described as the 
blueprint for the study. (68) A prospective, contextual and descriptive research 
design was used. 
 
A prospective study is one where the variables are measured during the time 
the study takes place (69, 70). This study was prospective as the data was 
collected when the study took place. 
 
Context refers to the setting for an event, the “small scale world” (68). This 
study was conducted contextually in the recovery room of operating theatres 
at CHBAH. 
 
A descriptive research design is used to observe, describe and document 
occurrences as they happen in real life situations (70). This study was 
descriptive as it described the occurrence of PORC in patients who have 
received intermediate acting NDMRs. 
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3.5.2 Study population 
 
The study population included ASA 1 to 3 patients who had undergone 
elective surgery and received an intermediate acting NDMR. 
 
3.5.3 Study sample 
 
Sample size 
 
Sample size is determined not just by the nature of the design study but also 
by the degree of precision required. Other factors that have to be taken into 
consideration when determining the sample size include precision of the data 
collection instrument, heterogeneity of the population and the incidence of the 
type of participant in the population. The more precise the data collection 
instrument is the smaller the sample size needed. Increasing demographic 
variables require increasing sample size. (68, 70, 71) 
 
Sampling describes the process of selecting a group of people with whom one 
wants to conduct the study. This subset of the population aims to represent 
the population in its entirety. (70)  
 
Studies have identified that the average incidence of PORC ranges from 17 to 
64% (48, 60, 64). It was estimated by the anaesthetists at CHBAH that the 
occurrence of PORC was about 20%. In consultation with a biostatistician 
using STRATA 12.5, it was postulated that 20% of our patients compared to 
an average of 40% of patients in the literature would have PORC, with a 5% 
level of confidence and 90% power, we needed 55 patients. 
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Sampling method 
 
A convenience sampling method will be employed for this study as a whole 
population study is limited by consent from participants and the possibility that 
the entire population will not be available or fulfil the inclusion criteria at the 
time of sampling. Convenience sampling can be considered as availability 
sampling as it entails choosing subjects that are readily available as 
participants for the study. This continues until an available sample size is 
reached. A disadvantage of this sampling method is that the data may not 
truly represent the population. (68) A convenience sampling method was 
employed for this study.  
 
Inclusion and exclusion criteria 
 
Inclusion criteria for this study were as follows: 
• adults 18 years and older 
• ASA 1 to 3 patients 
• surgery for an elective procedure 
• received an intermediate acting NDMR intraoperatively 
• extubated postoperatively. 
 
Exclusion criteria for this study were as follows: 
• patients who did not consent  
• no access to either ulnar nerve 
• patients who were unable to understand english. 
 
3.5.4 Data collection procedure 
 
Data was collected on days convenient for the researcher. This ensured that 
routine anaesthetic practice did not change while data was collected.  
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Preoperative consent was obtained from all ASA 1 to 3 patients booked for 
elective surgery. Consent was obtained the day before in the ward. Patients 
were invited to take part in the study. Patients who agreed received a patient 
information letter (Appendix 4) and informed written consent (Appendix 5) was 
obtained. The patient information letter and informed consent was written in a 
manner that is clear to the intended patients.  
 
The intraoperative management of the patient was at the discretion of the 
responsible anaesthetist i.e. if a NDMR was used or not; if neuromuscular 
function was monitored intraoperatively and/or if a reversal agent was used. 
The anaesthetist managing the patient intraoperatively was not alerted to the 
fact that neuromuscular monitoring would occur in the recovery room. 
 
On arrival to the operating theatre recovery room, once the anaesthetist 
responsible for the patient had signed the patient off as being adequately 
recovered, the TOF ratio was recorded by the researcher before accessing 
the anaesthetic record to ascertain which NDMR had been used. 
 
The researcher used an accelerometer. The accelerometer used was a TOF 
Watch® SX, produced by Organon, was on loan from the Department of 
Anaesthesiology and calibrated prior to use by local manufacturers. No further 
calibrations were done between patients. The TOF Watch® SX was 
exclusively used for research purposes. 
 
Electrodes of the accelerometer were placed over the ulnar nerve on the volar 
aspect of the wrist and the acceleration sensor was connected to an 
unrestricted thumb. The negative electrode was placed 1 cm proximal to the 
point at which the proximal flexion crease of the wrist crosses the flexor carpi 
ulnaris tendon. The positive electrode was placed 2 to 3 cm proximal to the 
negative electrode. A submaximal stimulus of 30 mA was applied and the 
accelerometer generated a ratio. This current intensity will induce only a 
fraction of fibres in a given nerve bundle. This would therefore reduce the 
twitch height but the ratio measured between the twitches remains the same 
(31). Measurements were repeated every 20 seconds until three 
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measurements were obtained. The average of these three measurements 
was used as the TOF ratio.  
 
Clinical assessment of neuromuscular function such as the ability to sustain a 
head lift and handgrip, the ability to cough, and oxygen saturations were 
carried out as these parameters are most commonly employed. 
 
The following data was captured on a data capture record (Appendix 6): 
• demographic data  
• age 
• gender  
• surgery  
• duration of surgery 
• drug names  
• TOF ratio measurements intraoperatively, if available 
• TOF ratio measurements done by the researcher in recovery room 
• clinical assessments 
• head lift 
• handgrip  
• cough 
• oxygen saturation. 
• body temperature. 
 
If a patient was found to have PORC, the researcher contacted the 
anaesthetist responsible for the patient and remained with the patient until the 
anaesthetist arrived. 
 
3.5.5 Data analysis 
 
Data was captured using Microsoft Office Excel® data spread sheets. Data 
was analysed with the assistance of a biostatistician and using STATISTICA, 
version 12.5. Frequencies and percentages were used to summarise the 
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results. Continuous variables were summarised using means and standard 
deviations if normally distributed and median and ranges if not normally 
distributed.  
3.6 Validity and reliability of the study 
 
Validity has been defined as “a measure of the truth or accuracy of a claim” 
(70). Reliability is represents a consistency of the measure achieved (69). 
 
Validity and reliability of this study was ensured by: 
• choosing an appropriate study design 
• using appropriate data gathering techniques 
• the researcher being the only data collector 
• the sample size being determined with assistance of a biostatistician 
• the data being analysed in consultation with a biostatistician 
• using a calibrated accelerometer  
• using the same accelerometer on all patients. 
 
3.7 Summary  
 
A detailed explanation of the research methodology has been presented in 
this chapter under the headings of study design, study population and study 
sample (including study size, sampling method, inclusion and exclusion 
criteria), description of data collection procedures, and the planned statistical 
analysis of the data.  
 
The following chapter details the data analysis and discussion of the results of 
the study. 
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Chapter 4: Results and discussion 
 
4.1 Introduction 
 
This chapter contains the results according to the objectives and the 
discussion thereof. The primary objectives of the study were to:  
• document if the TOF ratio was done before administration of an 
anticholinesterase and extubation by the attending anaesthesiologist 
• describe the clinical assessment of neuromuscular function 
• describe the occurrence of PORC as determined by the TOF ratio 
• describe the occurrence of factors contributing to PORC (hypothermia, 
NDMR, patients age and the use of an anticholinesterase). 
The secondary objectives were to: 
• compare with TOF ratio with the following clinical parameters: 
• saturation 
• handgrip 
• ability to cough 
• headlift 
• compare factors contributing to PORC (hypothermia, NDMR, patients 
age and the use of an anticholinesterase) with the TOF ratio. 
 
4.2 Sample realisation 
 
Data was collected over a period of three months (December 2014 to 
February 2015) and 55 patients were included in the study. 
 
4.3 Results 
 
Results are presented rounded off to two decimal points. Where appropriate, 
primary and secondary objectives will be presented together for ease of 
reading.  
  42 
4.3.1 Demographics 
 
Of the 55 patients, 30 (54.54%) were male. The mean age of patients 
assessed was 43.9 years (SD 15.80), ranging from 20 to 79 years.  
 
Twenty two (40%) of the patients presented for elective general surgery. 
Figure 4.1 exhibits the range of surgical disciplines from which patients 
presented. 
 
 
 
Figure 4.1 Surgical disciplines from which patients presented 
 
 
4.3.2 Primary objective: document if the TOF ratio was done before 
administration of an anticholinesterase and extubation by the attending 
anaesthesiologist 
 
Of the 55 patients, 3 (5.45%) according to the anaesthetic chart had received 
intraoperative neuromuscular monitoring. However the exact stimuli utilised 
and responses elicited were not recorded. It was also not evident whether the 
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use of neuromuscular monitoring intraoperatively changed practice in the 
administration of a reversal agent and extubation criteria. 
4.3.3 Primary objective: describe the clinical assessment of neuromuscular 
function 
 
Parameters utilised in this study to describe clinical assessment of adequate 
neuromuscular function include the oxygen saturation ≥ 90%; the ability to 
hold a hand grip for ≥ 5 seconds; (grip strength was not assessed) the ability 
to cough and to lift the head for ≥ 5 seconds.  
 
Supplemental oxygen was placed by the attending anaesthetist and whether 
placed routinely or as a therapeutic measurement was not determined by the 
researcher. Oxygen saturation ranged from 85 to 100% with a mean of 96.3% 
(SD 2.86). Forty two (76.36%) of the 55 patients were placed on supplemental 
oxygen in the recovery room. One (1.82%) patient on supplemental oxygen 
had a saturation < 90%. The clinical parameters of patients assessed are 
presented in Table 4.1. 
 
Table 4.1 Clinical parameters 
Parameter Adequate 
n (%) 
Inadequate 
n (%) 
Saturation 54 (98.18) 1 (1.82) 
Handgrip 46 (83.63) 9 (16.37) 
Ability to cough 51 (92.73) 4 (7.27) 
Headlift 44 (80) 11 (20) 
 
4.3.4 Primary objective: describe the occurrence of PORC as determined by 
the TOF ratio 
 
Out of the 55 patients, 25 (45.46%) patients fulfilled the criteria for PORC with 
a TOF ratio < 0.9. The TOF ratios obtained from patients is shown in Figure 
4.2 
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Figure 4.2 TOF ratio obtained from patients 
 
4.3.5 Primary objective: describe the occurrence of factors contributing to 
PORC (hypothermia, NDMR, patients age and use of an anticholinesterase)  
and 
Secondary objective: Compare the factors contributing to PORC 
(hypothermia, NDMR, patients age and use of an anticholinesterase) with the 
TOF ratio. 
 
Hypothermia 
 
Temperature within the study sample was normally distributed, with a mean of 
36.28 °C (SD 0.88), a minimum of 34.1 °C and a maximum of 38.4 °C.  
Table 4.2 presents the occurrence of PORC with temperature.  
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Table 4.2 The occurrence of PORC with temperature 
 Temp ≥ 35 
n (%) 
Temp < 35 
n (%) 
Total 
n (%) 
TOF RATIO< 
0.9 
23 (41.82) 2 (3.64) 25 (45.46) 
TOF RATIO≥ 
0.9 
29 (52.72) 1 (1.82) 30 (54.54) 
Total 52 (94.54) 3 (5.46) 55 (100) 
*p=0.59 
Of the 55 patients, 3 (5.46%) patients had a temperature of < 35 °C and were 
therefore hypothermic. Of those who were hypothermic 2 (66.67%) had 
PORC and 23 (44.23%) of those with a temperature above 35 °C presented 
with PORC.  
 
A Fisher’s exact was applied to determine if temperature in the patients with 
PORC differed from the patients without PORC. The p value of 0.59 was 
considered not significant.  
 
NDMR 
 
The occurrence of PORC in each of the intermediate NDMRs used is shown 
in Table 4.3. Rocuronium was the most frequently used NDMR with 31 
(56.36%) of 55 patients having received it.  
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Table 4.3 Occurrence of PORC with the different classes of NDMR 
 Atracurium 
n (%) 
Cisatracurium 
n (%) 
Rocuronium 
n (%) 
Vecuronium 
n (%) 
Total 
n (%) 
TOF 
ratio < 
0.9 
2 (3.63) 5 (9.09) 15 (27.27) 3 (5.45) 25 (45.56) 
TOF 
ratio ≥ 
0.9 
5 (9.09) 4 (7.27) 16 (29.09) 5 (9.09) 30 (54.54) 
Total 7 (12.72) 9 (16.36) 31 (56.36) 8 (14.54) 55 (100) 
*p = 0.72 
 
Of those that had received rocuronium 15 (48.39%) of the 31 patients 
presented with a TOF ratio < 0.9. Cisatracurium was the second most 
commonly used NDMR, 9 patients received cisatracurium and 5 (55.56%) of 
them developed PORC. Eight patients received vecuronium and 3 (37.50%) 
developed PORC. Atracurium was the least used NDMR with 7 patients 
having received it and 2 (28.57%) of them developed PORC. 
 
A Freeman-Halton extension of the Fisher exact test was applied to the above 
data and yielded a p-value of 0.72. The result is therefore not statistically 
significant.  
 
Patient age 
 
Patients between 18 and 80 years of age were included in data analysis. 
Forty five (81.81%) of the patients were < 60 years old and 10 were ≥ 60 
years old. Table 4.4 identifies the TOF ratios within the two age groups.  
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Table 4.4 TOF ratios in both age groups 
 < 60 
n (%) 
≥ 60 
n (%) 
Total 
n (%) 
TOF ratio < 0.9 21 (38.18) 4 (7.28) 25 (45.46) 
TOF ratio ≥ 0.9 24 (43.64) 6 (10.90) 30 (54.54) 
Total 45 (81.82) 10 (18.18) 55 (100) 
*p = 0.49 
 
A Fishers exact test was not statistically significant with a p value of 0.49 
 
Use of an anticholinesterase 
 
Neostigmine is currently the only reversal agent available at CHBAH. At the 
time of data collection there was a shortage of the anticholinergic 
glycopyralate and as a consequence this may have impacted on the results. 
Figure 4.3 illustrates the practice of anticholinesterase and anticholinergic 
use.  
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Figure 4.3 The use of anticholinesterase and anticholinergic 
 
The occurrence of PORC in patients that received an anticholinesterase can 
be seen in Table 4.5.  
 
 
Table 4.5 The occurrence of PORC with the use of an anticholinesterase. 
 Received 
n (%) 
Did not receive 
n (%) 
Total 
n (%) 
TOF ratio < 0.9 19 (34.55) 6 (10.91) 25 (45.46) 
TOF ratio ≥ 0.9 29 (52.72) 1 (1.82) 30 (54.54) 
Total 48 (87.27) 7 (12.73) 55 (100) 
*p = 0.03 
 
Of the 55 patients, 48 (87.27%) received a reversal agent and 19 (39.58%) of 
them subsequently presented with PORC. Seven (12.73%) patients did not 
receive an anticholinesterase and 6 (85.71%) of them presented with PORC. 
55 patients 
 
Neostigmine  2.5 mg 
48 (87.27%) pts 
No reversal agent 
 7 (12%) pts 
 
Atropine 
7 (12.73%) pts 
Glycopyralate 0.4 mg 
41 (85.45%) pts 
 
 
0.5 mg 
2 (3.64%) pts 
1 mg 
5 (9.09%) pts 
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A Fishers exact test yielded a p value of 0.03 which is considered statistically 
significant. Therefore there is an association between the use of an 
anticholinesterase and PORC. 
 
4.3.6 Secondary objective: compare clinical assessment with TOF 
 
Table 4.6 compares the clinical assessment with the TOF. Passing the clinical 
assessment meant that they could lift their heads for ≥ 5 seconds sustain a 
handgrip ≥ 5 seconds, able to cough and maintain oxygen saturations ≥ 90% 
with or without supplemental oxygen. A TOF ratio of ≥ 0.9 was considered 
adequate reversal. 
 
Table 4.6 Clinical assessment against TOF 
 Clinical assessment 
pass 
n (%) 
Clinical assessment 
fail 
n (%) 
TOF ratio < 0.9 20 (36) 5 (9) 
TOF ratio ≥ 0.9 24 (44) 6 (11) 
*p = 0.63 
 
A Fishers exact test was performed comparing the clinical assessment 
against the TOF ratio results. The p value was 0.63 was considered not 
significant.  
 
4.4 Discussion 
 
This study aimed to describe the occurrence of PORC in the recovery room in 
patients who have received an intermediate acting NDMR intraoperatively at 
CHBAH. This study was executed in conditions of daily practice at CHBAH. At 
the time of data collection intermittent drug shortages of glycopyralate and 
atracurium were present. This study provides data on the prevalence of 
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residual paralysis in the recovery room, which has not previously been 
assessed at CHBAH. The occurrence of PORC was found to be 45.46%. 
Research done internationally over the last 30 years has identified that the 
average incidence of PORC ranges from 17 to 64% (10, 12, 18). A study 
performed at Universitas Hospital in Bloemfontein in 2004, produced a 
prevalence of 42.9% when a TOF ratio < 0.9 was used and only 17.1% if a 
TOF ratio < 0.8 was used. A TOF ratio < 0.8 was the diagnostic criterion for 
PORC in 2004 (19). These results are similar to the results achieved in this 
study. 
 
Estimates of the occurrence of PORC vary widely in the literature. This may 
be due to different patient demographics, practices of using reversal agents 
and the use of intraoperative neuromuscular monitoring. The occurrence of 
PORC found is still high considering that one of the first studies to identify the 
incidence was done by Viby-Mogensen et al (65) in 1979. All patients tested 
in their study received a long acting nondepolarising neuromuscular blocker. 
They used a TOF ratio of < 0.7 as the diagnostic criterion and found that 42% 
of patients had residual block despite having adequate recovery clinically. (65) 
If the new criterion of a TOF ratio < 0.9 had been used the incidence would 
have been 72% (21).  
 
It is essential to consider why the occurrence of PORC is still regarded as 
being relatively infrequent even though several studies (11, 19) including this 
research report have shown that PORC is a common occurrence. Many 
anaesthetist still rely on clinical parameters to exclude PORC which has been 
shown to be inaccurate (6, 8). The side effects of PORC with a TOF ratio > 
0.7 are not usually life threatening and may therefore be perceived as less 
important (7).  
 
Results from the secondary objectives should be interpreted with caution, as 
the sample size was not calculated to power the comparisons. 
 
 Of the 55 patients included in this study, 44 (80%) passed the clinical 
assessment done by the researcher. Of these 44 patients, 20 (36%) who were 
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clinically assessed to be reversed had a TOF ratio < 0.9. A further 6 (11%) of 
the 55 patients failed the clinical assessment done by the researcher and had 
a TOF ratio ≥ 0.9. A comparison between objective testing using the TOF ratio 
and the subjective clinical assessment was not statistically significant. The 
parameters used in this study are those commonly employed by most 
anaesthetists in the recovery room at CHBAH to determine if patients are 
ready for discharge. Other parameters such as measuring the negative 
inspiratory pressure are not routinely used, as there are no pressure gauges 
available for this measurement in CHBAH recovery room. 
 
Two (3.64%) of the 55 patients had a TOF ratio < 0.5. These patients required 
supplemental oxygen in the recovery area and one of them nonetheless had a 
saturation of < 90%. These 2 (3.64%) patients passed all other clinical 
parameters tested in the study. According to the literature patients with a TOF 
ratio < 0.6 should be able to present with a head lift and handgrip for three 
seconds, open eyes wide and stick out their tongue but the vital capacity and 
negative inspiratory pressures are reduced (7, 12, 15). 
 
The selection of NDMR played no statistically significant role in the 
development of PORC. However patients who received cistatracurium 
presented with a higher percentage of PORC relative to the total number of 
patients that received cisatracurium i.e. 5 (55.56%) out of the 9 patients that 
received cisatracurium presented with PORC. On further observations 1 of the 
2 patients that presented with a TOF ratio < 0.5 had received cisatracrium.  
 
Maybauer et.al (66) found a higher incidence of PORC in patients who 
received cisatracurium when compared to rocuronium. This is in keeping with 
findings in this study where 55.56% of all patients who received cisatracurium 
developed PORC compared to 48.39% of those who received rocuronium. 
The dosing of cisatracurium is known to influence its duration of action and at 
3 × ED 95 it acts as a long acting NDMR. Dosages of drugs were documented 
on the anaesthetic records however the weights of patients were not, as a 
result no conclusions could be drawn on the impact of cisatracurium on 
PORC.  
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The administration, or lack thereof of an anticholinesterase was found to 
contribute to the development of PORC. Of the 55 patients included in data 
analysis 48 (87.3%) received an anticholinesterase as a reversal agent and 7 
(12.7%) did not. Of the 7 that did not receive an anticholinesterase, 6 (86%) 
were found to have PORC. This is in keeping with results found in the 
literature. The reduction in the occurrence of PORC is further reduced when 
timing of administration of an anticholinesterase is determined by 
neuromuscular testing (21, 38). 
 
The occurrence of PORC is higher in patients who had a temperature < 35 °C 
(66.67%) compared to the patients with a temperature ≥ 35 °C (44.23%). This 
result is not statistically significant. A review article by Heier et.al (54) where 
the duration of action of NDMR and recovery time was increased by the 
reduced elimination rate. A 2 °C reduction in core body temperature can 
increase the duration of action of NDMRs by as much as 100%.  
 
The occurrence of PORC in patients over 60 years of age was not found to be 
higher than in younger patients. Pietraszewski et.al (32) found that 90% of all 
elderly patients (≥ 65) had residual paralysis when neuromuscular monitoring 
was not used. Elderly patients were twice as likely to develop residual 
paralysis when compared to younger patients.  
  
The dosing practices of NDMRs including the dose per kilogram, timing and 
frequency of administration play a vital role in the development of PORC (7, 
66). Other factors which may also increase the occurrence of PORC including 
commonly used drugs like magnesium were not included as part of data 
collection and therefore their impact on the occurrence of PORC is unknown. 
Magnesium is a calcium antagonist; this reduces the release of acetylcholine 
from the presynaptic terminal of the neuromuscular junction resulting in 
prolonged neuromuscular blockade. 
 
The introduction of sugammadex has the potential to significantly reduce the 
occurrence of PORC. The costs associated with the impact of inadequate 
  53 
reversal including prolonged hospital stay and patient morbidity outweigh the 
cost of sugammadex. The single exit price for an ampoule of sugammadex is 
one thousand and two hundred rand compared to neostigmine which is five 
rand for a 2,5 mg vial. A review article by Paton et al(72) looked at the cost 
effectiveness of sugammadex when compared to neostigmine. Although 
sugammadex is more expensive that neostigmine it has the ability to reverse 
profound neuromuscular blockade by encapsulating and removing the 
aminosteroidal NDMR from the neuromuscular junction unlike neostigmine 
which has a ceiling dose effect. This means that the patient spends less time 
in theatre waiting for neuromuscular recovery thereby reducing theatre costs. 
Sugammadex can also prove to be life saving in situations where an 
unanticipated difficult airway is encountered consequently the benefits far out 
way the cost. 
 
This study identified that the occurrence of PORC at CHBAH is still high as 
45.46% of all patients who presented to the recovery room had a TOF ratio < 
0.9. Neuromuscular monitoring was recorded as having been done in 5.45% 
of the study sample. The values of neuromuscular monitoring were not 
recorded on the anaesthetic chart and it is not know if neuromuscular 
monitoring changed the anaesthetic practice intraoperatively. The perceived 
incidence of PORC by anaesthetists at CHBAH is unknown, but founded on 
results obtained in this study it is under estimated. 
 
4.5 Summary 
 
In this chapter the results and discussion of the results were presented. In the 
following and final chapter the summary, limitations, recommendations and 
conclusion will be addressed. 
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Chapter 5: Summary, limitations, recommendations 
and conclusion 
 
5.1 Introduction 
 
In this chapter, the aim and objectives, a study summary, the limitations, 
recommendations and conclusion will be presented. 
 
5.2 Study summary 
 
5.2.1 Aim of the study 
 
The aim of this study was to describe the occurrence of PORC in the recovery 
room in patients who have received intermediate acting NDMRs 
intraoperatively at CHBAH. 
 
5.2.2 Objectives of the study  
 
The primary objectives of the study were to:  
• document if the TOF ratio was done before administration of an 
anticholinesterase and extubation by the attending anaesthesiologist 
• describe the clinical assessment of neuromuscular function 
• describe the occurrence of PORC as determined by the TOF ratio 
• describe the occurrence of factors contributing to PORC (hypothermia, 
NDMR, patients age and the use of an anticholinesterase). 
 
The secondary objectives were to: 
• compare with TOF ratio with the following clinical parameters: 
• saturation 
• handgrip 
• ability to cough 
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• headlift 
• Compare factors contributing to PORC (hypothermia, NDMR, patients age 
and the use of an anticholinesterase) with the TOF ratio. 
 
5.2.3 Summary of methodology 
 
This study was a prospective, contextual and descriptive study on a sample 
that consisted of ASA 1 to 3 adult patients who had received an intermediate 
acting NDMR during elective surgery and were subsequently extubated. 
 
In consultation with a biostatistician it was estimated that a sample of 55 
patients was needed. A convenience sampling method was used. Potential 
patients were identified and invited to participate in the study and given an 
information letter (Appendix 4). Those agreeing were consented  (Appendix 
5). Patients were excluded from the study if they did not consent, if there was 
an inability to use either ulnar nerve during testing and if they did not 
understand English. 
 
Patients were assessed in the recovery room once they had been discharged 
by the their attending anaesthetist. A TOF Watch ® accelerometer was used 
to test the TOF ratio using either ulnar nerve on the volar aspect of the wrist. 
Clinical parameters tested included the ability to sustain a head lift and 
handgrip, the ability to cough, oxygen saturation and temperature. Details 
regarding the anaesthetic were obtained from the anaesthetic record and 
recorded on the data collection record.  Data was collected from December 
2014 to February 2015. Using Microsoft Excel® 2010, data was captured 
onto spread sheets. Statistical analyses were done using STATISTICA 
version 12.5. A p value < 0.05 was considered significant. 
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5.2.4 Summary of results 
 
Of the 55 patients in the study, 25 (45.46%) had a TOF ratio < 0.9 which 
fulfills the criterion for PORC. Intraoperative neuromuscular monitoring was 
documented to have been done in 5.45% of the study sample. Hypothermia 
did not statistically contribute to the development of PORC (p= 0.2) and 
niether did the type of  NDMR used (p=0.72). However a high percentage of 
patients who were hypothermic presented with PORC  (66.67% ) i.e 2 of the 3 
patients that were hypothermic had a TOF ratio < 0.9 . Patients who received 
cisatracurium had a higher occurrence of PORC with 55.56% having a TOF 
ratio < 0.9. Patients older than 60 years were not found to have a higher risk 
of developing PORC (p=0.49). The use of an anticholinesterase in reducing 
the occurrence of PORC was identified however it did not completely reduce 
the risk (p=0.03). Seven of the 55 patients in the study did not receive an 
anticholinesterase and 6 (85.71%) of them subsequently presented with 
PORC. Clinical assessment of adequate neuromuscular function did have any 
association with the TOF ratio objective testing.  
 
5.3 Limitations of the study 
 
 
The study is contextual and therefore results may not be generalisable  to 
other instituitions, however the results have the potential to improve clinical 
practice at CHBAH. 
The dosing practices of NDMRs towards developing PORC is important. This 
study did not collect data on the weight of patients prior to surgery and the 
dose per kilogram, frequency and timing of administration of NDMRs was not 
collected . The duration of surgery was noted however timing of last dosages 
was not evident on anaesthetic records and therefore could not be analysed 
to determine if it contributed to developing PORC. 
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This study was not powered to determine if contributing factors like 
temperature, NDMR, patients age and use of anticholinesterase increased the 
risk of developing PORC. 
Pulse oximetery of patients were recorded but whether oxygen was placed 
routinely or as a treament measure was not identified and as such no 
associations can be made on whether patients who had a TOF ratio < 0.9 
had a higher prevalance of low oxygen saturations. 
Clinical parameters tested are those that are commonly employed in CHBAH, 
however other parameters can also be used such as inspiratory pressures 
which may be better at clinically assessing adequate neuromuscular function. 
A supramaximal stimulus of 50 mA is recommended for testing using an 
accelerometer but because of the degree of pain associated with 50 mA a 
submaximal stimulus of 30 mA was used as in previous studies. 
Drug shortages at the time of data collection include glycopyralate and 
atracurium and therefore may not reflect usual practices at CHBAH. 
 
5.4 Recommendations 
 
5.4.1 Clinical practice 
 
Intraoperative neuromuscular monitoring has the potential to decrease the 
occurrence of PORC  by increasing the awareness and the diagnosis of 
PORC. Accelerometers should be available in all theatres and neuromuscular 
monitoring should become routine. Drug dosing practices should be guided by 
the results obtained from intraoperative neuromuscular monitoring and by 
patient factors such as age, body mass index and temperature. Utilise 
NDMRs only when necessary and preferably not for short cases. 
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Anticholinesterase as a reversal agent should only be administered once four 
twitches are elicited on a TOF count. Delay extubation and keep patients 
sedated if the TOF ratio < 0.9. 
 
5.4.2 Further research 
 
Should the above mentioned recommendations be implemented at CHBAH, it 
is recommended that their effectiveness be followed up. Further research 
adequately powered to indentify the contributing factors of PORC is also 
needed. Dosing practices of NDMRs in relation to the weight of the patient,  
duration of surgery and timing of the last dose towards the development of 
PORC also needs to be researched. Research to identify the patient related 
complications as a consequence of PORC is also recommended to highlight 
short term and long term effects. 
 
5.4 Conclusion 
 
The prevalence of PORC found in this study remains a clinically significant 
problem. Of interest was the finding that the majority of patients were clinically 
reversed but 45. 46 % still had PORC. This study also found that the use of 
an anticholinesterase contributed to reducing the risk of developing of PORC 
but did not reduce the occurrence of PORC. The duration of surgery, NDMR’s 
used, age and temperature of the patients did not show any statistical 
significance in contributing to the occurrence of PORC. 
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Appendix 4: Patient information letter 
  
Hello,  
 
My name is Sakeena Hassim. I am a doctor currently specialising at Wits University. As part 
of the course requirement, I am expected to conduct research and would like to invite you to 
take part in my study. The title of my study is: The occurrence of residual curarisation in 
postoperative patients at an academic hospital.  
 
During your operation, you will be given medicine to make your muscles weak. This medicine 
will help the doctor to do the operation. At the end of the operation, the doctor will check that 
your muscles are strong enough again so that you can breath on your own. If they are not 
strong enough the doctor will give you medication to make them strong again. I would like to 
check if your muscles are strong enough for you to breath when you get to the recovery room 
after your operation. To do this I will use a little machine that will give you a light shock on 
your wrist. You will feel this but it will be not painful and you might not remember this. I will 
also ask you to squeeze my hand, to lift your head up for a short while, to cough and I will 
take your temperature. If I find that your muscles are not strong enough I will stay with you 
and ask someone to go and fetch the doctor that put you to sleep for your operation so that 
he can check you again. 
 
You do not have to take part in this study if you do not want to, or you can decide to take part 
and then change your mind and this will not affect your treatment in anyway. If you decide to 
take part in my study I will keep all your information anonymous, meaning that no one will 
know that you took part as I will not record your name anywhere. Also your information will be 
locked away safely and only my supervisors and I will be able to see it.  
 
The study has obtained approval from the Human Research Ethics Committee of the 
University of the Witwatersrand. If you have any questions, please feel free to ask me. You 
will be given a copy of this form to keep. If you have any questions later on, you can contact 
me on 011 933 9334 or the Chairman of the Ethics Committee on 011 717 1234.  
 
Thank you for reading this letter.  
 
Yours sincerely 
 
Dr Sakeena Hassim 
zakke77@yahoo.com 
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Appendix 5: Informed consent 
 
Informed consent form  
 
YOU ARE MAKING A DECISION WHETHER OR NOT TO 
PARTICIPATE. YOUR SIGNATURE INDICATES THAT YOU 
HAVE DECIDED TO PARTICIPATE, HAVING READ THE 
INFORMATION PROVIDED ABOVE AND HAVING YOUR 
QUESTIONS ANSWERED TO YOUR SATISFACTION.  
 
Print name of participant:_______________________________  
 
Signature of participant: ________________________________ 
Hospital number:______________________________________ 
Study Number:________________________________________ 
 
Print name of researcher/person taking consent: ___________ 
 
Signature of researcher/person taking consent: ____________ 
 
Date (dd/mm/yy): 
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Appendix 6: Data Collection record 
 
Study number: 
Date:  
 
Demographics 
Gender: 
 
Age: 
Discipline: 
 
 
TOF Ratio 
Measurements:  
 
 
Clinical Parameters of adequate neuromuscular function: 
 
Headlift                                                           sec 
Handgrip                                                           sec 
Saturation                                                          % 
Ability to cough               
               YES 
            
                  NO 
 
Clinical Parameters: 
O2 Facemask                                                   litres/min 
Temperature                                                   ° C 
 
 
 
            Male           Female 
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Anaesthetic Drugs used, time and dosage: 
 
Was neuromuscular 
monitoring used 
 
 
              YES 
 
                NO 
Duration of anaesthetic  
 
 
 
 
Drug  
  
Atracurium  
Cisatracurium  
Rocuronium  
Vecuronium  
Neostigmine  
Atropine  
Glycopyralate  
Maintenance 
